A Cisplatin‐Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy

Na Wang, Zhigang Wang, Zoufeng Xu, Xianfeng Chen, Guangyu Zhu

Research output: Contribution to journalArticlepeer-review

Abstract

The efficacy of conventional chemotherapy is hindered by cancer cells' escape from the immune system. Herein, we report a multifunctional nanohybrid system for effective immuno-chemotherapy against cervical cancer. This nanohybrid contains both immune checkpoint inhibitor and cisplatin anticancer prodrug, showing improved cellular accumulation and increased binding of Pt to DNA and resulting in elevated apoptosis than using cisplatin alone when tested in cervical cancer cells. Intriguingly, the use of immune checkpoint inhibitors enables the inhibition of indoleamine-2,3-dioxygenase and reverses immunosuppressive T cells to recognize cancer cells, leading to T cell proliferation and activation, cancer cell cycle arrest, and ultimately increased cancer cell death. Overall, we provide a novel strategy using a multifunctional nanohybrid system to boost the antitumor activity of cisplatin, the gold standard chemotherapeutic treatment for cervical cancer.
Original languageEnglish
Pages (from-to)3426-3430
JournalAngewandte Chemie International Edition
Volume57
Issue number13
Early online date13 Mar 2018
DOIs
Publication statusE-pub ahead of print - 13 Mar 2018

Fingerprint Dive into the research topics of 'A Cisplatin‐Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy'. Together they form a unique fingerprint.

Cite this